{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:41:07Z","timestamp":1761363667985,"version":"build-2065373602"},"reference-count":15,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,10,23]]},"DOI":"10.1248\/bpb.b25-00378","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:07:55Z","timestamp":1761170875000},"page":"1566-1571","source":"Crossref","is-referenced-by-count":0,"title":["Preferential Recognition of Drug-Induced Altered Self-Presentation on Tumor Cells, but Not Host Cells, by CD8&lt;sup&gt;+&lt;\/sup&gt; T Cells for Eliciting Anti-Tumor Immunity"],"prefix":"10.1248","volume":"48","author":[{"given":"Takeshi","family":"Susukida","sequence":"first","affiliation":[{"name":"Section of Host Defences, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Aoki","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260\u20138675, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Section of Host Defences, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. <i>Lancet<\/i>, <b>398<\/b>, 1002\u20131014 (2021).","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. <i>JAMA Netw. Open<\/i>, <b>2<\/b>, e192535 (2019).","DOI":"10.1001\/jamanetworkopen.2019.2535"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Grau Bejar JF, Yaniz Galende E, Zeng Q, Genestie C, Rouleau E, de Bruyn M, Klein C, Le Formal A, Edmond E, Moreau M, Plat A, Gouy S, Maulard A, Pautier P, Michels J, Oaknin A, Colomba-Blameble E, Leary A. Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. <i>J. Immunother. Cancer<\/i>, <b>12<\/b>, e009143 (2024).","DOI":"10.1136\/jitc-2024-009143"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. <i>Immunity<\/i>, <b>28<\/b>, 822\u2013832 (2008).","DOI":"10.1016\/j.immuni.2008.04.020"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, Miles JJ, Kjer-Nielsen L, Gras S, Williamson NA, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. <i>Nature<\/i>, <b>486<\/b>, 554\u2013558 (2012).","DOI":"10.1038\/nature11147"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Rodriguez-N\u00f3voa S, Soriano V. Current trends in screening across ethnicities for hypersensitivity to abacavir. <i>Pharmacogenomics<\/i>, <b>9<\/b>, 1531\u20131541 (2008).","DOI":"10.2217\/14622416.9.10.1531"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Susukida T, Sasaki SI, Shirayanagi T, Aoki S, Ito K, Hayakawa Y. Drug-induced altered self-presentation increases tumor immunogenicity. <i>Biomed. Pharmacother.<\/i>, <b>165<\/b>, 115241 (2023).","DOI":"10.1016\/j.biopha.2023.115241"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Susukida T, Aoki S, Kogo K, Fujimori S, Song B, Liu C, Sekine S, Ito K. Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice. <i>Arch. Toxicol.<\/i>, <b>92<\/b>, 1177\u20131188 (2018).","DOI":"10.1007\/s00204-017-2112-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Susukida T, Kuwahara S, Song B, Kazaoka A, Aoki S, Ito K. Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity. <i>Commun. Biol.<\/i>, <b>4<\/b>, 1137 (2021).","DOI":"10.1038\/s42003-021-02657-2"},{"key":"10","unstructured":"10) <i>Guide for the Care and Use of Laboratory Animals<\/i>. 8th ed., National Academic Press, Washington DC (2011)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, Teixeira-Guedes C, Soares-Maia R, da Costa RG, Colaco B, Pires MJ, Colaco J, Ferreira R, Ginja M. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. <i>Lab Anim. (NY)<\/i>, <b>42<\/b>, 217\u2013224 (2013).","DOI":"10.1038\/laban.254"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. <i>Cancer Gene Ther.<\/i>, <b>29<\/b>, 10\u201321 (2022).","DOI":"10.1038\/s41417-021-00303-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kazaoka A, Kumagai K, Matsushita J, Aida T, Kuwahara S, Aoki S, Ito K. Pathological changes in various organs in HLA-B*57: 01 transgenic mice with abacavir-induced skin eruption. <i>Toxicol. Res.<\/i>, <b>40<\/b>, 223\u2013235 (2024).","DOI":"10.1007\/s43188-023-00220-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) O\u2019Melia MJ, Rohner NA, Manspeaker MP, Francis DM, Kissick HT, Thomas SN. Quality of CD8<sup>+<\/sup> T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. <i>Sci. Adv.<\/i>, <b>6<\/b>, eabd7134 (2020).","DOI":"10.1126\/sciadv.abd7134"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Barbarino JM, Kroetz DL, Altman RB, Klein TE. PharmGKB summary: abacavir pathway. <i>Pharmacogenet. Genomics<\/i>, <b>24<\/b>, 276\u2013282 (2014).","DOI":"10.1097\/FPC.0000000000000040"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/10\/48_b25-00378\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:36:45Z","timestamp":1761363405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/10\/48_b25-00378\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00378","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"b25-00378"}}